Clinical Profile of Glycaemia’s Level in Schizophrenic Patients at KNPC
Updated: Feb 18, 2023
Author: Saleh Irakoze Health Maintenance Organization In Africa HMO-AFRICA
Africa Co-author: Sudi Ndikumana
Saleh Irakoze Health Maintenance Organization In Africa HMO-AFRICA
'Unlike the belief of several people, schizophrenia is not fatality. Schizophrenic patients are neither possessed, nor dangerous or immunised against metabolic pathologies, they are the most vulnerable; they need to access to the best Healthcare.'
Abstract:
Schizophrenic patients can present metabolic pathologies linked to intrinsic and extrinsic factors. New studies have proved the association between schizophrenia and glucose dysregulation. In addition, the change of life style and the use of antipsychotics can be also associated with metabolic pathologies. Even if schizophrenic patients are more concerned by metabolic pathologies linked to glycaemia’s level disruptions; however, in Burundi, there are no any study according to glycaemia’s level disruptions in schizophrenic patients.
Aim: The aim of this study was to establish the clinical profile of glycaemia’s level to schizophrenia patients in Kamenge Neuropsychiatric Centre (KNPC). Therefore, the results of it could help to highlight the impacts of those glycaemia’s level disruptions to the schizophrenic patient’s wellbeing and especially to brain.
Methods: From 1 July 2017 to 10 September of the same year, three variables [demography, treatment and illness antecedent] were assessed in prospective study of 26 patients at the time of hospital entree and 18 patients after 30 days of treatment. Our task was to take blood glucose level when schizophrenia patient was admitting in the hospital and after 30 days of treatment in the same schizophrenic patients. The range of [4.2- 6.4 mmol/l] was used are glycaemia’s physiological limit.
Results: The prevalence of glycaemia’s level disruption was significantly higher when schizophrenic patients were admitting to the hospital [high glycaemia’s level cases (23.07%); low glycaemia’s level (23.07%)] and after 30 days of treatment [high glycaemia’s level cases (5.55%); low glycaemia’s level (27.78%)]. However, after 30 days of treatment, the cases of low glycaemia’s level were significantly represented. The treatment showed more impacts to glycaemia’s level disruption; schizophrenic patients under two psychotropic drugs were highly exposed to low glycaemia level [patient under 1 drug (0.00%), patient under 2 drugs (44.44%) and patient under 3 drugs (33.33%)]. In addition, the demography [Residence, sex and age of the patient] was significantly associated with glycaemia’s level disruption in schizophrenic patients.
Conclusion: Schizophrenia is one of the brain disease, which can affect the brain function, and the glucose is the essential fuel for the brain; the glycaemia’s level disruptions could be the risk factor of the brain damage. In schizophrenic patient, while schizophrenia is affecting their brain function, the glycaemia’s level disruptions are damaging the brain. To balance or control glycaemia’s level in Schizophrenic patient could contribute to the treatment and good recovery of wellbeing in schizophrenic patient.
